PROVIDENCE - real-world study in patients with HER2-positive unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan and offered PRO-React Onco - PROVIDENCE

Study identifier:D9673R00028

ClinicalTrials.gov identifier:NCT05573893

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Prospective non-interventional study (NIS) to examine the impact of eHealth support on patient-reported outcomes and on real world clinical data in patients with HER2-positive unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan

Medical condition

Breast Neoplasms

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

390

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 30 Jun 2023
Estimated Primary Completion Date: 30 Sept 2030
Estimated Study Completion Date: 30 Sept 2030

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo

Inclusion and exclusion criteria